Effect of aminoglycoside dosing on magnesium levels in hospitalised patients
Khalid M. Alkharfy
Correspondence information about the author Khalid M. Alkharfy
Email the author Khalid M. Alkharfy
, Correspondence information about the author Khalid M. AlkharfyEmail the author Khalid M. AlkharfyDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia
Article InfoTo view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect.
Fig. 1
Serum magnesium changes at 0, 24 and 48 h of aminoglycoside therapy following (A) multiple-daily dosing and (B) once-daily dosing, (*) P < 0.05.
Aminoglycosides are bactericidal antibiotics used in the systemic treatment of serious Gram-negative infections. Multiple-daily dosing (MDD) has been the conventional method to administer aminoglycosides; however, use of once-daily dosing (ODD) has gained popularity during the last two decades. This is because ODD has a post-antibiotic effect, at least as effective as MDD, and may actually be less nephrotoxic than more frequent dosing [1]. Aminoglycoside-induced nephrotoxicity generally occurs after 5–7 days of treatment and is present as non-oligouric renal failure with a slow rise in serum creatinine [2].
To access this article, please choose from the options below
Purchase access to this article
Claim Access
If you are a current subscriber with Society Membership or an Account Number, claim your access now.
Subscribe to this title
Purchase a subscription to gain access to this and all other articles in this journal.
Institutional Access
Visit ScienceDirect to see if you have access via your institution.
© 2007 Elsevier B.V. and the International Society of Chemotherapy. Published by Elsevier Inc. All rights reserved.
